| 1 |
26446141 | Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. | 2016 Feb |
2 |
| 2 |
26896706 | Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism. | 2016 Apr 13 |
2 |
| 3 |
27198207 | Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1. | 2016 Dec |
3 |
| 4 |
25940823 | Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. | 2015 Aug |
2 |
| 5 |
24265353 | The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen. | 2014 Jan |
3 |
| 6 |
25114852 | Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen. | 2014 Aug 10 |
2 |
| 7 |
22041137 | Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. | 2012 |
2 |
| 8 |
21870861 | A mechanistic hypothesis for the cytochrome P450-catalyzed cis-trans isomerization of 4-hydroxytamoxifen: an unusual redox reaction. | 2011 Sep 26 |
2 |
| 9 |
20052538 | Orally administered endoxifen is a new therapeutic agent for breast cancer. | 2010 Jul |
2 |
| 10 |
20425602 | CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. | 2010 Jan |
2 |
| 11 |
19574470 | Pharmacogenomics of tamoxifen therapy. | 2009 Oct |
2 |
| 12 |
15111773 | Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. | 2004 May |
6 |